X
CPRX

Xponance’s Catalyst Pharmaceutical CPRX Stock Holding History

Xponance’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$503K Buy
16,018
+655
+4% +$19.3K ﹤0.01% 1097
2026
Q1 		$380K Buy
15,363
+1,804
+13% +$43K ﹤0.01% 1148
2025
Q4 		$316K Sell
13,559
-565
-4% -$12.6K ﹤0.01% 1150
2025
Q3 		$278K Sell
14,124
-3,694
-21% -$76K ﹤0.01% 1205
2025
Q2 		$387K Sell
17,818
-870
-5% -$20.5K ﹤0.01% 1046
2025
Q1 		$453K Sell
18,688
-75
-0.4% -$1.69K ﹤0.01% 968
2024
Q4 		$392K Buy
18,763
+1,189
+7% +$25.5K ﹤0.01% 1031
2024
Q3 		$349K Buy
+17,574
New +$326K ﹤0.01% 1043

Other funds holding CPRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Xponance's CPRX Position: Q2 2026 in Review

Xponance increased its Catalyst Pharmaceutical (CPRX) stake by 4.3% in Q2 2026, buying an estimated $19.3K and bringing the position to 16,018 shares worth $503K. The position accounts for ﹤0.01% of the portfolio, ranked #1097.

Xponance first reported a position in CPRX in Q3 2024 and has held it in 8 quarters since. 396 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

  • Xponance held 16,018 shares of Catalyst Pharmaceutical worth $503K as of Q2 2026.
  • Xponance bought 655 Catalyst Pharmaceutical shares in Q2 2026, an estimated $19.3K.
  • Catalyst Pharmaceutical made up ﹤0.01% of Xponance's portfolio in Q2 2026, its #1097 holding.
  • Xponance first reported a position in Catalyst Pharmaceutical in Q3 2024 and has held it in 8 quarters since.
  • 396 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on Xponance's 13F filing for Q2 2026, filed 10 Aug 2026.